Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1999 May 15;340(Pt 1):77–84.

Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.

M S Stack 1, S Gately 1, L M Bafetti 1, J J Enghild 1, G A Soff 1
PMCID: PMC1220224  PMID: 10229661

Abstract

Angiostatin, a kringle-containing fragment of plasminogen, is a potent inhibitor of angiogenesis. The mechanism(s) responsible for the anti-angiogenic properties of angiostatin are unknown. We now report that human angiostatin blocks plasmin(ogen)-enhanced in vitro invasion of tissue plasminogen activator (t-PA)-producing endothelial and melanoma cells. Kinetic analyses demonstrated that angiostatin functions as a non-competitive inhibitor of extracellular-matrix (ECM)-enhanced, t-PA-catalysed plasminogen activation, with a Ki of 0.9+/-0.03 microM. This mechanism suggests that t-PA has a binding site for the inhibitor angiostatin, as well as for its substrate plasminogen that, when occupied, prevents ternary complex formation between t-PA, plasminogen and matrix protein. Direct binding experiments confirmed that angiostatin bound to t-PA with an apparent Kd [Kd(app)] of 6.7+/-0.7 nM, but did not bind with high affinity to ECM proteins. Together, these data suggest that angiostatin in the cellular micro-environment can inhibit matrix-enhanced plasminogen activation, resulting in reduced invasive activity, and suggest a biochemical mechanism whereby angiostatin-mediated regulation of plasmin formation could influence cellular migration and invasion.

Full Text

The Full Text of this article is available as a PDF (187.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bafetti L. M., Young T. N., Itoh Y., Stack M. S. Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol Chem. 1998 Jan 2;273(1):143–149. doi: 10.1074/jbc.273.1.143. [DOI] [PubMed] [Google Scholar]
  2. Bizik J., Lizonová A., Stephens R. W., Grófová M., Vaheri A. Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion. Cell Regul. 1990 Nov;1(12):895–905. doi: 10.1091/mbc.1.12.895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bizik J., Stephens R. W., Grofova M., Vaheri A. Binding of tissue-type plasminogen activator to human melanoma cells. J Cell Biochem. 1993 Mar;51(3):326–335. doi: 10.1002/jcb.240510312. [DOI] [PubMed] [Google Scholar]
  4. Bugge T. H., Flick M. J., Daugherty C. C., Degen J. L. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 1995 Apr 1;9(7):794–807. doi: 10.1101/gad.9.7.794. [DOI] [PubMed] [Google Scholar]
  5. Bugge T. H., Kombrinck K. W., Xiao Q., Holmbäck K., Daugherty C. C., Witte D. P., Degen J. L. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood. 1997 Dec 1;90(11):4522–4531. [PubMed] [Google Scholar]
  6. Cao Y., Ji R. W., Davidson D., Schaller J., Marti D., Söhndel S., McCance S. G., O'Reilly M. S., Llinás M., Folkman J. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem. 1996 Nov 15;271(46):29461–29467. doi: 10.1074/jbc.271.46.29461. [DOI] [PubMed] [Google Scholar]
  7. Cao Y., O'Reilly M. S., Marshall B., Flynn E., Ji R. W., Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest. 1998 Mar 1;101(5):1055–1063. doi: 10.1172/JCI1558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J. J., Collen D., Mulligan R. C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994 Mar 31;368(6470):419–424. doi: 10.1038/368419a0. [DOI] [PubMed] [Google Scholar]
  9. Claesson-Welsh L., Welsh M., Ito N., Anand-Apte B., Soker S., Zetter B., O'Reilly M., Folkman J. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A. 1998 May 12;95(10):5579–5583. doi: 10.1073/pnas.95.10.5579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dong Z., Kumar R., Yang X., Fidler I. J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 1997 Mar 21;88(6):801–810. doi: 10.1016/s0092-8674(00)81926-1. [DOI] [PubMed] [Google Scholar]
  11. Enghild J. J., Valnickova Z., Thøgersen I. B., Pizzo S. V., Salvesen G. An examination of the inhibitory mechanism of serpins by analysing the interaction of trypsin and chymotrypsin with alpha 2-antiplasmin. Biochem J. 1993 May 1;291(Pt 3):933–938. doi: 10.1042/bj2910933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Folkman J., Haudenschild C. C., Zetter B. R. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5217–5221. doi: 10.1073/pnas.76.10.5217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 1992 Jun 5;267(16):10931–10934. [PubMed] [Google Scholar]
  14. Gately S., Twardowski P., Stack M. S., Cundiff D. L., Grella D., Castellino F. J., Enghild J., Kwaan H. C., Lee F., Kramer R. A. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10868–10872. doi: 10.1073/pnas.94.20.10868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gately S., Twardowski P., Stack M. S., Patrick M., Boggio L., Cundiff D. L., Schnaper H. W., Madison L., Volpert O., Bouck N. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 1996 Nov 1;56(21):4887–4890. [PubMed] [Google Scholar]
  16. Geppert A. G., Binder B. R. Allosteric regulation of tPA-mediated plasminogen activation by a modifier mechanism: evidence for a binding site for plasminogen on the tPA A-chain. Arch Biochem Biophys. 1992 Sep;297(2):205–212. doi: 10.1016/0003-9861(92)90663-h. [DOI] [PubMed] [Google Scholar]
  17. Griscelli F., Li H., Bennaceur-Griscelli A., Soria J., Opolon P., Soria C., Perricaudet M., Yeh P., Lu H. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6367–6372. doi: 10.1073/pnas.95.11.6367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hori A., Sasada R., Matsutani E., Naito K., Sakura Y., Fujita T., Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 1991 Nov 15;51(22):6180–6184. [PubMed] [Google Scholar]
  19. Hoylaerts M., Rijken D. C., Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912–2919. [PubMed] [Google Scholar]
  20. Ji W. R., Barrientos L. G., Llinás M., Gray H., Villarreal X., DeFord M. E., Castellino F. J., Kramer R. A., Trail P. A. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun. 1998 Jun 18;247(2):414–419. doi: 10.1006/bbrc.1998.8825. [DOI] [PubMed] [Google Scholar]
  21. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993 Apr 29;362(6423):841–844. doi: 10.1038/362841a0. [DOI] [PubMed] [Google Scholar]
  22. Knudsen B. S., Silverstein R. L., Leung L. L., Harpel P. C., Nachman R. L. Binding of plasminogen to extracellular matrix. J Biol Chem. 1986 Aug 15;261(23):10765–10771. [PubMed] [Google Scholar]
  23. Lannutti B. J., Gately S. T., Quevedo M. E., Soff G. A., Paller A. S. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res. 1997 Dec 1;57(23):5277–5280. [PubMed] [Google Scholar]
  24. Lijnen H. R., Bachmann F., Collen D., Ellis V., Pannekoek H., Rijken D. C., Thorsen S. Mechanisms of plasminogen activation. J Intern Med. 1994 Oct;236(4):415–424. doi: 10.1111/j.1365-2796.1994.tb00819.x. [DOI] [PubMed] [Google Scholar]
  25. Lijnen H. R., Ugwu F., Bini A., Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry. 1998 Apr 7;37(14):4699–4702. doi: 10.1021/bi9731798. [DOI] [PubMed] [Google Scholar]
  26. Menashi S., Lu H., Soria C., Legrand Y. Endothelial cell proteases: physiological role and regulation. Baillieres Clin Haematol. 1993 Sep;6(3):559–576. doi: 10.1016/s0950-3536(05)80188-x. [DOI] [PubMed] [Google Scholar]
  27. Mignatti P., Rifkin D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1993 Jan;73(1):161–195. doi: 10.1152/physrev.1993.73.1.161. [DOI] [PubMed] [Google Scholar]
  28. Millauer B., Shawver L. K., Plate K. H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994 Feb 10;367(6463):576–579. doi: 10.1038/367576a0. [DOI] [PubMed] [Google Scholar]
  29. Moser T. L., Enghild J. J., Pizzo S. V., Stack M. S. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem J. 1995 May 1;307(Pt 3):867–873. doi: 10.1042/bj3070867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Moser T. L., Enghild J. J., Pizzo S. V., Stack M. S. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem. 1993 Sep 5;268(25):18917–18923. [PubMed] [Google Scholar]
  31. Moser T. L., Stack M. S., Asplin I., Enghild J. J., Højrup P., Everitt L., Hubchak S., Schnaper H. W., Pizzo S. V. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2811–2816. doi: 10.1073/pnas.96.6.2811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Moser T. L., Young T. N., Rodriguez G. C., Pizzo S. V., Bast R. C., Jr, Stack M. S. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer. 1994 Feb 15;56(4):552–559. doi: 10.1002/ijc.2910560415. [DOI] [PubMed] [Google Scholar]
  33. Müllertz S. Fibrinolysis: an overview. Semin Thromb Hemost. 1984 Jan;10(1):1–5. doi: 10.1055/s-2007-1004402. [DOI] [PubMed] [Google Scholar]
  34. Neuman T., Stephens R. W., Salonen E. M., Timmusk T., Vaheri A. Induction of morphological differentiation of human neuroblastoma cells is accompanied by induction of tissue-type plasminogen activator. J Neurosci Res. 1989 Jul;23(3):274–281. doi: 10.1002/jnr.490230305. [DOI] [PubMed] [Google Scholar]
  35. O'Reilly M. S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996 Jun;2(6):689–692. doi: 10.1038/nm0696-689. [DOI] [PubMed] [Google Scholar]
  36. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct 21;79(2):315–328. doi: 10.1016/0092-8674(94)90200-3. [DOI] [PubMed] [Google Scholar]
  37. Patterson B. C., Sang Q. A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem. 1997 Nov 14;272(46):28823–28825. doi: 10.1074/jbc.272.46.28823. [DOI] [PubMed] [Google Scholar]
  38. Pepper M. S., Vassalli J. D., Wilks J. W., Schweigerer L., Orci L., Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem. 1994 Aug;55(4):419–434. doi: 10.1002/jcb.240550403. [DOI] [PubMed] [Google Scholar]
  39. Rijken D. C., Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981 Jul 10;256(13):7035–7041. [PubMed] [Google Scholar]
  40. Sato Y., Okamura K., Morimoto A., Hamanaka R., Hamaguchi K., Shimada T., Ono M., Kohno K., Sakata T., Kuwano M. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res. 1993 Feb;204(2):223–229. doi: 10.1006/excr.1993.1028. [DOI] [PubMed] [Google Scholar]
  41. Schnaper H. W., Barnathan E. S., Mazar A., Maheshwari S., Ellis S., Cortez S. L., Baricos W. H., Kleinman H. K. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol. 1995 Oct;165(1):107–118. doi: 10.1002/jcp.1041650114. [DOI] [PubMed] [Google Scholar]
  42. Silverstein R. L., Harpel P. C., Nachman R. L. Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin. J Biol Chem. 1986 Jul 25;261(21):9959–9965. [PubMed] [Google Scholar]
  43. Sim B. K., O'Reilly M. S., Liang H., Fortier A. H., He W., Madsen J. W., Lapcevich R., Nacy C. A. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 1997 Apr 1;57(7):1329–1334. [PubMed] [Google Scholar]
  44. Soff G. A., Jackman R. W., Rosenberg R. D. Expression of thrombomodulin by smooth muscle cells in culture: different effects of tumor necrosis factor and cyclic adenosine monophosphate on thrombomodulin expression by endothelial cells and smooth muscle cells in culture. Blood. 1991 Feb 1;77(3):515–518. [PubMed] [Google Scholar]
  45. Stack M. S., Gray R. D., Pizzo S. V. Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain. Cancer Res. 1993 May 1;53(9):1998–2004. [PubMed] [Google Scholar]
  46. Stack M. S., Moser T. L., Pizzo S. V. Binding of human plasminogen to basement-membrane (type IV) collagen. Biochem J. 1992 May 15;284(Pt 1):103–108. doi: 10.1042/bj2840103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Stack M. S., Rinehart A. R., Pizzo S. V. Comparison of plasminogen binding and activation on extracellular matrices produced by vascular smooth muscle and endothelial cells. Eur J Biochem. 1994 Dec 15;226(3):937–943. doi: 10.1111/j.1432-1033.1994.00937.x. [DOI] [PubMed] [Google Scholar]
  48. Stack S., Gonzalez-Gronow M., Pizzo S. V. Regulation of plasminogen activation by components of the extracellular matrix. Biochemistry. 1990 May 22;29(20):4966–4970. doi: 10.1021/bi00472a029. [DOI] [PubMed] [Google Scholar]
  49. Stathakis P., Fitzgerald M., Matthias L. J., Chesterman C. N., Hogg P. J. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem. 1997 Aug 15;272(33):20641–20645. doi: 10.1074/jbc.272.33.20641. [DOI] [PubMed] [Google Scholar]
  50. Takano S., Gately S., Neville M. E., Herblin W. F., Gross J. L., Engelhard H., Perricone M., Eidsvoog K., Brem S. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 1994 May 15;54(10):2654–2660. [PubMed] [Google Scholar]
  51. Tanaka T., Cao Y., Folkman J., Fine H. A. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 1998 Aug 1;58(15):3362–3369. [PubMed] [Google Scholar]
  52. Tsirka S. E., Bugge T. H., Degen J. L., Strickland S. Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin. Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9779–9781. doi: 10.1073/pnas.94.18.9779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Wiman B., Lijnen H. R., Collen D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta. 1979 Jul 25;579(1):142–154. doi: 10.1016/0005-2795(79)90094-1. [DOI] [PubMed] [Google Scholar]
  54. Wohl R. C., Summaria L., Robbins K. C. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37 degrees C. J Biol Chem. 1980 Mar 10;255(5):2005–2013. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES